ATE292628T1 - Chinazolinderivate - Google Patents

Chinazolinderivate

Info

Publication number
ATE292628T1
ATE292628T1 AT00962682T AT00962682T ATE292628T1 AT E292628 T1 ATE292628 T1 AT E292628T1 AT 00962682 T AT00962682 T AT 00962682T AT 00962682 T AT00962682 T AT 00962682T AT E292628 T1 ATE292628 T1 AT E292628T1
Authority
AT
Austria
Prior art keywords
sup
sub
quinazoline derivatives
aurora
kinase
Prior art date
Application number
AT00962682T
Other languages
English (en)
Inventor
Andrew Austen Mortlock
Nicholas John Keen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE292628T1 publication Critical patent/ATE292628T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Ropes Or Cables (AREA)
  • Earth Drilling (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00962682T 1999-09-21 2000-09-18 Chinazolinderivate ATE292628T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922173.1A GB9922173D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003562 WO2001021595A1 (en) 1999-09-21 2000-09-18 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
ATE292628T1 true ATE292628T1 (de) 2005-04-15

Family

ID=10861219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962682T ATE292628T1 (de) 1999-09-21 2000-09-18 Chinazolinderivate

Country Status (23)

Country Link
US (1) US7105669B1 (de)
EP (1) EP1218357B1 (de)
JP (1) JP2003509498A (de)
KR (1) KR20020029136A (de)
CN (1) CN1391560A (de)
AT (1) ATE292628T1 (de)
AU (1) AU7433000A (de)
BG (1) BG106535A (de)
BR (1) BR0014136A (de)
CA (1) CA2384284A1 (de)
CZ (1) CZ20021007A3 (de)
DE (1) DE60019317T2 (de)
EE (1) EE200200148A (de)
GB (1) GB9922173D0 (de)
HK (1) HK1046687A1 (de)
HU (1) HUP0204226A3 (de)
IL (1) IL148498A0 (de)
IS (1) IS6309A (de)
NO (1) NO20021395L (de)
PL (1) PL354972A1 (de)
SK (1) SK3842002A3 (de)
WO (1) WO2001021595A1 (de)
ZA (1) ZA200201831B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
RU2267489C2 (ru) 2000-08-21 2006-01-10 Астразенека Аб Производные хиназолина, способ их получения и фармацевтическая композиция
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
DE60233736D1 (de) * 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
EP1471910A2 (de) 2002-01-17 2004-11-03 Neurogen Corporation Substituirte chinazolin-4-ylamine analogue als capsaicinreceptoren-modulatoren
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
JP4237242B2 (ja) 2004-10-12 2009-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1856053A1 (de) * 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Cinnamid- und hydrocinnamid-derivate mit raf-kinase hemmender aktivität
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
WO2006118231A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090076075A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
CA2652341A1 (en) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc. Identification of cdki pathway inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2247579B1 (de) * 2008-01-17 2012-04-18 Bayer Pharma Aktiengesellschaft Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ 4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN105777654B (zh) * 2016-03-28 2018-03-27 贵州大学 一种含喹唑啉的阿魏酸酯类衍生物、其制备方法和用途
EP3762379A1 (de) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identifizierung und verwendung von erk5-inhibitoren
JP2024515204A (ja) * 2021-04-22 2024-04-05 ボロノイ インコーポレイテッド ヘテロアリール誘導体化合物およびその用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
WO2004013091A2 (en) * 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases

Also Published As

Publication number Publication date
HUP0204226A3 (en) 2003-07-28
PL354972A1 (en) 2004-03-22
HUP0204226A2 (en) 2003-05-28
NO20021395L (no) 2002-05-15
CZ20021007A3 (cs) 2002-06-12
EP1218357A1 (de) 2002-07-03
ZA200201831B (en) 2003-08-27
JP2003509498A (ja) 2003-03-11
SK3842002A3 (en) 2002-10-08
IL148498A0 (en) 2002-09-12
IS6309A (is) 2002-03-19
WO2001021595A1 (en) 2001-03-29
BG106535A (bg) 2002-12-29
US7105669B1 (en) 2006-09-12
DE60019317D1 (de) 2005-05-12
EE200200148A (et) 2003-04-15
KR20020029136A (ko) 2002-04-17
EP1218357B1 (de) 2005-04-06
AU7433000A (en) 2001-04-24
CA2384284A1 (en) 2001-03-29
DE60019317T2 (de) 2006-03-09
NO20021395D0 (no) 2002-03-20
BR0014136A (pt) 2002-05-21
HK1046687A1 (zh) 2003-01-24
GB9922173D0 (en) 1999-11-17
CN1391560A (zh) 2003-01-15

Similar Documents

Publication Publication Date Title
ATE292628T1 (de) Chinazolinderivate
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
DE69903923D1 (de) Bizyklische pyrrolderivate als mcp-1 inhibitoren
NO20004090D0 (no) Kjemiske forbindelser
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
TR200200749T2 (tr) Kinazolin bileşikleri ve bunları içeren farmasötik bileşikler.
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
DK1044967T3 (da) 2-pyridinylguanidinurokinaseinhibitor
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
ATE374189T1 (de) Phthalazinon-derivate als pde 4 hemmer
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties